The Future of Pharma

SWISS MADE
Next capital increase
Put yourself on the list of interested parties. We will inform you in good time, before the IPO, about the next financing round.

Harnessing the potential of medicinal cannabis

Leading manufacturer

MediCrops, based in Switzerland, is one of, if not the leading research and development company.  The premium quality medicinal cannabis products are made for the European market, with a focus on the German-speaking region.

Medicinal cannabis and MediCrops

Medicinal cannabis market

Cannabis is cultivated and exported worldwide. Cultivation in Europe often takes place in so-called indoor facilities, especially in Germany, the Netherlands and Italy.

The responsible Committee of the Council of States, i.e. the body that represents the cantons in the Swiss parliament, has given the green light by a clear majority for cultivation, production, trade and consumption to be newly regulated. Accordingly, the Narcotics Act will be amended to facilitate the distribution of cannabis for medicinal purposes and to allow its export.

This has created the basis for a regulated and legal cannabis market in Switzerland with great growth potential.

One of the most promising markets of the future

Biggest Global
Growth Market:
0

BILLIONS OF US DOLLARS
(UP TO 2026)

Global Market
Growth:
0 %

(CAGR 2021–2026)

MediCrops Investment
Requirement:
0

MILLION SWISS FRANCS (BY 2025)

Exponential Growth
MediCrops:
0 %

(CAGR 2022-2025)

Market Potential
in Europe:
0

BILLIONS OF US DOLLARS
(UP TO 2026)

Spectacular Growth
in Europe:
0 %

(CAGR 2021–2026)

Plot Size:
 
0

Square meter

Production Scalability
up to Double:
0

Square meter

Be part of the success

Profitable investment

Building on its positioning as a high-quality and fully integrated producer of medicinal cannabis, MediCrops is expected to benefit from the rapidly growing markets in Germany, Austria and Switzerland and gain a significant market share.

Milestones

0000
0000
0000